Welcome To Diurnal
Diurnal is a UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.
Mission Statement
To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.
Latest News
-
14 Jan2021
Business and trading update
Continued growth in Alkindi sales despite impact of Covid-19 on hospital visits and new launches
-
14 Jan2021
Licencing agreement with Eton Pharmaceuticals for Alkindi® extended to Canada
Expands Alkindi® availability outside of key European and US commercial markets
-
13 Jan2021
Diurnal signs agreement with Er-Kim for the distribution of Alkindi® and Chronocort® in Turkey
This agreement adds to the Company's ongoing strategy for commercialisation of its lead products by optimising market access outside of key European markets through entering marketing and distribution agreements with companies focused on niche and orphan conditions.